Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Halozyme Therapeutics Stock Quote

Halozyme Therapeutics (NASDAQ: HALO)

$38.36
(-0.9%)
-$0.36
Price as of April 16, 2024, 3:59 p.m. ET

Halozyme Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
HALO +8.61% +136.67% +18.80% +833%
S&P +22.34% +74.52% +11.78% +352%

Halozyme Therapeutics Company Info

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

News & Analysis

The Fool has written over 100 articles on Halozyme Therapeutics.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.